A Phase I/II (Single Center, Open, Phase I and Multicenter, Double-Blinded, Randomized, Placebo-Controlled, Phase II) Trial to Evaluate the Safety and Immunogenicity of the AdCLD-CoV19-1 OMI Administered as a Booster to Healthy Adults Aged 19 Years Old and Above
Latest Information Update: 23 Jul 2024
At a glance
- Drugs AdCLD-CoV19 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Cellid Company
Most Recent Events
- 17 Jul 2024 Status changed from active, no longer recruiting to completed.
- 09 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 15 Nov 2022 Status changed from active, no longer recruiting to recruiting.